Literature DB >> 33922418

Echinochrome A Treatment Alleviates Fibrosis and Inflammation in Bleomycin-Induced Scleroderma.

Gyu-Tae Park1, Jung-Won Yoon1, Sang-Bin Yoo1, Young-Chul Song1, Parkyong Song2, Hyoung-Kyu Kim3, Jin Han3, Sung-Jin Bae4, Ki-Tae Ha5, Natalia P Mishchenko6, Sergey A Fedoreyev6, Valentin A Stonik6, Moon-Bum Kim7, Jae-Ho Kim1.   

Abstract

Scleroderma is an autoimmune disease caused by the abnormal regulation of extracellular matrix synthesis and is activated by non-regulated inflammatory cells and cytokines. Echinochrome A (EchA), a natural pigment isolated from sea urchins, has been demonstrated to have antioxidant activities and beneficial effects in various disease models. The present study demonstrates for the first time that EchA treatment alleviates bleomycin-induced scleroderma by normalizing dermal thickness and suppressing collagen deposition in vivo. EchA treatment reduces the number of activated myofibroblasts expressing α-SMA, vimentin, and phosphorylated Smad3 in bleomycin-induced scleroderma. In addition, it decreased the number of macrophages, including M1 and M2 types in the affected skin, suggesting the induction of an anti-inflammatory effect. Furthermore, EchA treatment markedly attenuated serum levels of inflammatory cytokines, such as tumor necrosis factor-α and interferon-γ, in a murine scleroderma model. Taken together, these results suggest that EchA is highly useful for the treatment of scleroderma, exerting anti-fibrosis and anti-inflammatory effects.

Entities:  

Keywords:  echinochrome A; fibrosis; inflammation; scleroderma; systemic sclerosis

Year:  2021        PMID: 33922418     DOI: 10.3390/md19050237

Source DB:  PubMed          Journal:  Mar Drugs        ISSN: 1660-3397            Impact factor:   5.118


  36 in total

1.  Alternatively activated alveolar macrophages in pulmonary fibrosis-mediator production and intracellular signal transduction.

Authors:  Dmitri V Pechkovsky; Antje Prasse; Florian Kollert; Kathrin M Y Engel; Jan Dentler; Werner Luttmann; Karlheinz Friedrich; Joachim Müller-Quernheim; Gernot Zissel
Journal:  Clin Immunol       Date:  2010-07-31       Impact factor: 3.969

Review 2.  Transforming growth factor β--at the centre of systemic sclerosis.

Authors:  Robert Lafyatis
Journal:  Nat Rev Rheumatol       Date:  2014-08-19       Impact factor: 20.543

Review 3.  Systemic sclerosis: a prototypic multisystem fibrotic disorder.

Authors:  John Varga; David Abraham
Journal:  J Clin Invest       Date:  2007-03       Impact factor: 14.808

Review 4.  Protective and pathogenic functions of macrophage subsets.

Authors:  Peter J Murray; Thomas A Wynn
Journal:  Nat Rev Immunol       Date:  2011-10-14       Impact factor: 53.106

5.  Collagen metabolites in urine in localized scleroderma (morphoea).

Authors:  T Ammitzbøll; J Serup
Journal:  Acta Derm Venereol       Date:  1984       Impact factor: 4.437

6.  Alternatively activated macrophages (M2 macrophages) in the skin of patient with localized scleroderma.

Authors:  Nobuyo Higashi-Kuwata; Takamitsu Makino; Yuji Inoue; Motohiro Takeya; Hironobu Ihn
Journal:  Exp Dermatol       Date:  2009-03-03       Impact factor: 3.960

7.  Amelioration of endotoxin-induced uveitis treated with the sea urchin pigment echinochrome in rats.

Authors:  Anton Lennikov; Nobuyoshi Kitaichi; Kousuke Noda; Kazuomi Mizuuchi; Ryo Ando; Zhenyu Dong; Junichi Fukuhara; Satoshi Kinoshita; Kenichi Namba; Shigeaki Ohno; Susumu Ishida
Journal:  Mol Vis       Date:  2014-02-07       Impact factor: 2.367

Review 8.  The Interaction of the Metallo-Glycopeptide Anti-Tumour Drug Bleomycin with DNA.

Authors:  Vincent Murray; Jon K Chen; Long H Chung
Journal:  Int J Mol Sci       Date:  2018-05-04       Impact factor: 5.923

9.  Echinochrome A Reduces Colitis in Mice and Induces In Vitro Generation of Regulatory Immune Cells.

Authors:  Su-Jeong Oh; Yoojin Seo; Ji-Su Ahn; Ye Young Shin; Ji Won Yang; Hyoung Kyu Kim; Jin Han; Natalia P Mishchenko; Sergey A Fedoreyev; Valentin A Stonik; Hyung-Sik Kim
Journal:  Mar Drugs       Date:  2019-10-31       Impact factor: 5.118

Review 10.  Current perspectives on the immunopathogenesis of systemic sclerosis.

Authors:  Patrizia Fuschiotti
Journal:  Immunotargets Ther       Date:  2016-04-11
View more
  5 in total

Review 1.  Multifaceted Clinical Effects of Echinochrome.

Authors:  Hyoung Kyu Kim; Elena A Vasileva; Natalia P Mishchenko; Sergey A Fedoreyev; Jin Han
Journal:  Mar Drugs       Date:  2021-07-26       Impact factor: 5.118

2.  Echinochrome A Treatment Alleviates Atopic Dermatitis-like Skin Lesions in NC/Nga Mice via IL-4 and IL-13 Suppression.

Authors:  Hyeong Rok Yun; Sang Woo Ahn; Bomin Seol; Elena A Vasileva; Natalia P Mishchenko; Sergey A Fedoreyev; Valentin A Stonik; Jin Han; Kyung Soo Ko; Byoung Doo Rhee; Jung Eun Seol; Hyoung Kyu Kim
Journal:  Mar Drugs       Date:  2021-11-01       Impact factor: 5.118

3.  NRF2 activation by 2-methoxycinnamaldehyde attenuates inflammatory responses in macrophages via enhancing autophagy flux.

Authors:  Bo-Sung Kim; Minwook Shin; Kyu-Won Kim; Ki-Tae Ha; Sung-Jin Bae
Journal:  BMB Rep       Date:  2022-08       Impact factor: 5.041

4.  Mesoporous silica-coated silver nanoparticles as ciprofloxacin/siRNA carriers for accelerated infected wound healing.

Authors:  Qiqi Liu; Ying Zhang; Jingkai Huang; Zhourui Xu; Xiang Li; Jingyu Yang; Haoqiang Huang; Shiqi Tang; Yujuan Chai; Jinbo Lin; Chengbin Yang; Jia Liu; Suxia Lin
Journal:  J Nanobiotechnology       Date:  2022-08-23       Impact factor: 9.429

5.  Echinochrome A Inhibits Melanogenesis in B16F10 Cells by Downregulating CREB Signaling.

Authors:  Mi Ran Choi; Heejin Lee; Hyoung Kyu Kim; Jin Han; Jung Eun Seol; Elena A Vasileva; Natalia P Mishchenko; Sergey A Fedoreyev; Valentin A Stonik; Won Seok Ju; Dai-Jin Kim; Sang-Rae Lee
Journal:  Mar Drugs       Date:  2022-08-29       Impact factor: 6.085

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.